| Ticker Details |
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
|
| IPO Date: |
October 19, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.86B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.61 | 2.80%
|
| Avg Daily Range (30 D): |
$1.30 | 2.44%
|
| Avg Daily Range (90 D): |
$1.42 | 2.69%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.21M |
| Avg Daily Volume (30 D): |
1.57M |
| Avg Daily Volume (90 D): |
1.65M |
| Trade Size |
| Avg Trade Size (Sh.): |
62 |
| Avg Trade Size (Sh.) (30 D): |
49 |
| Avg Trade Size (Sh.) (90 D): |
51 |
| Institutional Trades |
| Total Institutional Trades: |
6,542 |
| Avg Institutional Trade: |
$2.95M |
| Avg Institutional Trade (30 D): |
$2.65M |
| Avg Institutional Trade (90 D): |
$2.61M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.7M |
| Avg Closing Trade (30 D): |
$7.57M |
| Avg Closing Trade (90 D): |
$8.09M |
| Avg Closing Volume: |
91.01K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-6.2
|
$-1.28
|
$-1.35
|
|
Diluted EPS
|
$-6.2
|
$-1.28
|
$-1.35
|
|
Revenue
|
$4.1M
|
$1.46M
|
$.86M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-568.53M
|
$-122.93M
|
$-130.61M
|
|
Operating Income / Loss
|
$-646.4M
|
$-130.25M
|
$-154.76M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$184.59M
|
$72.27M
|
$61.06M
|
|
PE Ratio
|
|
|
|
|
|
|